INOV8 Surgical Performs 1st Surgery using THINK Surgical’s Next-Generation Robot Technology for Knee Replacement

THINK Surgical, Inc., an innovator in the field of orthopedic active robot surgery, is pleased to announce that INOV8 Surgical is the first healthcare facility to utilize the second-generation TSolution One® Total Knee Application for total knee arthroplasty (TKA). Stefan Kreuzer, M.D., orthopedic surgeon, and the founder of INOV8 Orthopedics, performed the first procedure with the new system on August 24th at INOV8 Surgical Ambulatory Surgery Center (ASC) in Houston, Texas.

THINK’s TSolution One system is the only robot system for TKA that supports an open implant library, giving surgeons the largest choice of implant options from different manufactures facilitating broad patient customization.

“My team and I are pleased to offer our patients the accuracy and reproducibility made possible in joint replacement procedures by THINK Surgical’s next-generation active robot,” said Dr. Kreuzer*. “Adoption of this advanced technology demonstrates our commitment to deliver exceptional outcomes for our patients.”

Dr. Kreuzer incorporated the first-generation TSolution One system into the INOV8 Surgical orthopedics program in early 2020, shortly after initial FDA clearance. INOV8 Surgical is a leading healthcare facility specializing in outpatient total joint procedures.

“We are very excited to have our latest robotic technology available to patients through the INOV8 Surgical ASC,” said Jay Yang, acting CEO and COO of THINK Surgical, Inc. “Our innovative engineers continue to advance robotic orthopedic surgery as demonstrated by our next-generation system and by future product launches.”

The TSolution One system consists of TPLAN®, a 3D pre-surgical planning workstation, and TCAT®, an active robot. Pre-surgical planning allows the surgeon to design and prepare the patient’s personalized joint replacement surgical plan in a virtual environment. The active robot aids the surgeon in executing the preoperative surgical plan with precise, automated cutting and removal of the diseased bone and cartilage. The TSolution One system assists surgeons with optimizing joint implant placement based on each patient’s unique anatomy.

The first full commercial launch was announced in 2020.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version